MeSH Review:
Cystectomy
- Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Celis, J.E., Celis, P., Ostergaard, M., Basse, B., Lauridsen, J.B., Ratz, G., Rasmussen, H.H., Orntoft, T.F., Hein, B., Wolf, H., Celis, A. Cancer Res. (1999)
- Bladder cancer immunotherapy. Lamm, D.L., Thor, D.E., Stogdill, V.D., Radwin, H.M. J. Urol. (1982)
- Severe cyclophosphamide-induced hemorrhagic cystitis successfully treated by total cystectomy with ileal neobladder substitution: a case report. Okaneya, T., Kontani, K., Komiyama, I., Takezaki, T. J. Urol. (1993)
- The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. Meyers, F.J., Palmer, J.M., Freiha, F.S., Harker, E.G., Shortliffe, L.D., Hannigan, J., McWhirter, K., Torti, F.M. J. Urol. (1985)
- Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Haab, F., Meulemans, A., Boccon-Gibod, L., Dauge, M.C., Delmas, V., Boccon-Gibod, L. Prostate (1995)
- Carcinoma of the urinary bladder in patients receiving cyclophosphamide. Wall, R.L., Clausen, K.P. N. Engl. J. Med. (1975)
- Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. Shipley, W.U., Prout, G.R., Einstein, A.B., Coombs, L.J., Wajsman, Z., Soloway, M.S., Englander, L., Barton, B.A., Hafermann, M.D. JAMA (1987)
- Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W.R., Fuks, Z., Reuter, V.E. J. Natl. Cancer Inst. (1992)
- p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. Shariat, S.F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G.E., Benedict, W.F., Lerner, S.P. J. Clin. Oncol. (2004)
- Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. Stricker, P.D., Grant, A.B., Hosken, B.M., Taylor, J.S. J. Urol. (1990)
- Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion. Donat, S.M., Slaton, J.W., Pisters, L.L., Swanson, D.A. J. Urol. (1999)
- Enhancing effect of partial cystectomy on rat urinary bladder carcinogenesis. Tsujihashi, H., Nakanishi, A., Matsuda, H., Uejima, S., Kurita, T. J. Urol. (1991)
- Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa. Treible, D.P., Skinner, D., Kasimain, D., Friedman, N.B., Kern, W.H. Urology (1987)
- Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder. Ek, A., Hellsten, S., Henrikson, H., Idwall, I., Lindholm, C.E., Lindholm, K., Mikulowski, P., Månsson, W. Scandinavian journal of urology and nephrology. (1984)
- Continent urinary diversion. A 5 1/2 year experience. Skinner, D.G., Lieskovsky, G., Boyd, S.D. Ann. Surg. (1988)
- Re: Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the surveillance, epidemiology, and end results program. Loughlin, K.R., Coogan, C.L., Sobel, D.L. J. Urol. (2006)
- p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy? Steiner, G., Bierhoff, E., Schmidt, D., Leissner, J., Wolf, H.K., Albers, P. Eur. J. Cancer (2000)
- Pheochromocytoma of the urinary bladder: a case report. Takezawa, Y., Inoue, M., Kurita, S., Nakata, S., Kobayashi, M., Kosaku, N., Yamanaka, H. Hinyokika kiyo. Acta urologica Japonica. (2001)
- A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study. Igawa, M., Urakami, S., Shirakawa, H., Shiina, H., Ishibe, T., Usui, T., Moriyama, H. Hiroshima J. Med. Sci. (1995)
- Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Kurahashi, T., Hara, I., Oka, N., Kamidono, S., Eto, H., Miyake, H. Clin. Cancer Res. (2005)
- Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center. Akkad, T., Gozzi, C., Deibl, M., Müller, T., Pelzer, A.E., Pinggera, G.M., Bartsch, G., Steiner, H. J. Urol. (2006)
- Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. Nieuwenhuijzen, J.A., Meinhardt, W., Horenblas, S. J. Urol. (2005)
- Endocrine-paracrine (APUD) cells of the human female urethra and paraurethral ducts. di Sant'Agnese, P.A., de Mesy Jensen, K.L. J. Urol. (1987)
- Bladder reconstruction in rabbits with glutaraldehyde-stabilized amniotic membranes. Norris, M.A., Cohen, M.S., Warren, M.M., Becker, S.N., Baur, P.S., Seybold, H.M. Urology (1982)
- Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Farrow, G.M., Utz, D.C., Rife, C.C., Greene, L.F. Cancer Res. (1977)
- Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. Herr, H.W., Pinsky, C.M., Whitmore, W.F., Sogani, P.C., Oettgen, H.F., Melamed, M.R. J. Urol. (1986)
- A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. Freiha, F., Reese, J., Torti, F.M. J. Urol. (1996)
- Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. Glick, S.H., Howell, L.P., White, R.W. J. Urol. (1996)
- Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. Martínez-Piñeiro, J.A., Jiménez León, J., Martínez-Piñeiro, L., Fiter, L., Mosteiro, J.A., Navarro, J., García Matres, M.J., Cárcamo, P. J. Urol. (1990)
- The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Inoue, K., Slaton, J.W., Karashima, T., Yoshikawa, C., Shuin, T., Sweeney, P., Millikan, R., Dinney, C.P. Clin. Cancer Res. (2000)
- Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. Shariat, S.F., Matsumoto, K., Kim, J., Ayala, G.E., Zhou, J.H., Jian, W., Benedict, W.F., Lerner, S.P. J. Urol. (2003)
- The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou, P., Christodoulou, P., Kapralos, P., Exarchakos, M., Bisbiroula, A., Hadjiyannakis, M., Georgountzos, C., Thomas-Tsagli, E. Pathol. Res. Pract. (1997)
- Prognostic significance of insulin-like growth factor (IGF) binding protein-2 to IGF-binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder. Miyake, H., Hara, I., Yamanaka, K., Muramaki, M., Eto, H. BJU international. (2005)
- Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Grossfeld, G.D., Carroll, P.R., Lindeman, N., Meng, M., Groshen, S., Feng, A.C., Hawes, D., Cote, R.J. Urology (2002)
- Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. Tester, W., Caplan, R., Heaney, J., Venner, P., Whittington, R., Byhardt, R., True, L., Shipley, W. J. Clin. Oncol. (1996)
- Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Stoehr, R., Knuechel, R., Boecker, J., Blaszyk, H., Schmitt, R., Filbeck, T., Hofstaedter, F., Hartmann, A. Lab. Invest. (2002)
- Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. Steinberg, G., Bahnson, R., Brosman, S., Middleton, R., Wajsman, Z., Wehle, M. J. Urol. (2000)
- Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. Waidelich, R., Stepp, H., Baumgartner, R., Weninger, E., Hofstetter, A., Kriegmair, M. J. Urol. (2001)